Venetoclax, an FDA-approved BCL-2 inhibitor that is revolutionizing care in some BCL-2-expressing hematological cancers, affords an intriguing therapeutic possibility to treat SS. Here, BCL2 is linked to hematopoietic and lymphoid cell neoplasm.